N/A
Completed N=732
Safety and Efficacy of Combigan® Ophthalmic Solution in Korea
Glaucoma, Open-Angle · Hypertension
Source: ClinicalTrials.gov NCT01987752 ↗
Enrolled (actual)
732
Serious AEs
0.0%
Results posted
Apr 2014
Primary outcomePrimary: Percentage of Participants Reporting Adverse Events — 6.56 Percentage of participants
Summary
This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of Combigan® (brimonidine tartrate/timolol maleate) Ophthalmic Solution in patients with Open Angle Glaucoma or Ocular hypertension with insufficient response to local beta blockers treated as per standard of care in clinical practice.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants Reporting Adverse Events |
6.56 | — |
| PRIMARY Percentage of Participants With Overall Improvement From Baseline in Intraocular Pressure (IOP) |
85.69 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with Open Angle Glaucoma or Ocular Hypertension treated with Combigan® Ophthalmic Solution as standard of care in clinical practice.
Exclusion Criteria
- None.
Data sourced from ClinicalTrials.gov (NCT01987752). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.